
Opinion|Videos|January 20, 2025
Overview of Teplizumab for Delaying Onset and Progression of Type 1 Diabetes
Panelists discuss how teplizumab, the first FDA-approved disease-modifying therapy for Type 1 diabetes, can delay disease onset by targeting CD3+ T cells and preserving beta cell function in high-risk individuals.
Advertisement
Episodes in this series

Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Accepts sNDA for Roflumilast Cream 0.3% to Treat Plaque Psoriasis in Children Aged 2 to 5 Years
2
Migraine Risk Rises With Unexpectedness of Daily Experiences, the "Surprisal" Factor
3
Alcohol Use at Any Level Tied to Increased Risk of Dementia: Daily Dose
4
Chronic Pain Linked to Greater Risk of Hypertension, Depression Mediates the Relationship
5


























































































































































































































































































